Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.

Golubovskaya V, O'Brien S, Ho B, Heffler M, Conroy J, Hu Q, Wang D, Liu S, Cance WG.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1613-31. doi: 10.1007/s00432-015-1924-3. Epub 2015 Feb 6.

PMID:
25656374
2.

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.

Golubovskaya VM, Ho B, Conroy J, Liu S, Wang D, Cance WG.

Cancers (Basel). 2014 Jan 21;6(1):166-78. doi: 10.3390/cancers6010166.

3.

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG.

BMC Cancer. 2013 Jul 11;13:342. doi: 10.1186/1471-2407-13-342.

4.

MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.

Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG.

Anticancer Agents Med Chem. 2014 Jan;14(1):18-28.

5.
6.

Focal adhesion kinase regulates expression of thioredoxin-interacting protein (TXNIP) in cancer cells.

Ho B, Huang G, Golubovskaya VM.

Anticancer Agents Med Chem. 2014 Jan;14(1):3-8.

7.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

8.

Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Ho B, Olson G, Figel S, Gelman I, Cance WG, Golubovskaya VM.

J Biol Chem. 2012 May 25;287(22):18656-73. doi: 10.1074/jbc.M111.322883. Epub 2012 Apr 5.

9.

A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG.

Carcinogenesis. 2012 May;33(5):1004-13. doi: 10.1093/carcin/bgs120. Epub 2012 Mar 7.

10.

Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Cance WG.

Anticancer Agents Med Chem. 2013 May;13(4):546-54.

11.

A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.

Golubovskaya VM, Palma NL, Zheng M, Ho B, Magis A, Ostrov D, Cance WG.

Anticancer Agents Med Chem. 2013 May;13(4):532-45.

Supplemental Content

Loading ...
Support Center